Literature DB >> 11826947

Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

Eric Wooltorton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11826947      PMCID： PMC99278     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  1 in total

1.  Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.

Authors:  M McMorran; D Vu
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262
  1 in total
  13 in total

1.  Rosiglitazone (Avandia) and macular edema.

Authors:  Claire Kendall; Eric Wooltorton
Journal:  CMAJ       Date:  2006-02-08       Impact factor: 8.262

2.  Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.

Authors:  Patrizio Tatti; Franco Arrigoni; Adriano Longobardi; Flavia Costanza; Patrizia Di Blasi; Domenico Merante
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

3.  Drug vs class-specific black box warnings: does one bad drug spoil the bunch?

Authors:  Stacie B Dusetzina; G Caleb Alexander
Journal:  J Gen Intern Med       Date:  2011-06       Impact factor: 5.128

Review 4.  Heart failure induced by non-cardiac drugs.

Authors:  Lars Slørdal; Olav Spigset
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.

Authors:  Priyesh A Patel; Li Liang; Prateeti Khazanie; Bradley G Hammill; Gregg C Fonarow; Clyde W Yancy; Deepak L Bhatt; Lesley H Curtis; Adrian F Hernandez
Journal:  Circ Heart Fail       Date:  2016-07       Impact factor: 8.790

6.  Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.

Authors:  Juan F Mosley; Lillian Smith; Emily Everton; Chris Fellner
Journal:  P T       Date:  2015-07

7.  Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone.

Authors:  Ferruh Artunc; Diana Sandulache; Omaima Nasir; Krishna M Boini; Björn Friedrich; Norbert Beier; Edith Dicks; Sven Pötzsch; Karin Klingel; Kerstin Amann; Bonnie L Blazer-Yost; Wolfgang Scholz; Teut Risler; Dietmar Kuhl; Florian Lang
Journal:  Pflugers Arch       Date:  2008-01-03       Impact factor: 3.657

Review 8.  Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

Authors:  André J Scheen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

Authors:  Andrew Cohen; Atonu Rabbani; Nilay Shah; G Caleb Alexander
Journal:  Diabetes Care       Date:  2010-01-26       Impact factor: 19.112

10.  Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.

Authors:  Koichi Node; Teruo Inoue; Valentin Boyko; Ilan Goldberg; Enrique Z Fisman; Yehuda Adler; Ehud Schwammenthal; Zipora Matas; Solomon Behar; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-01-28       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.